GAITHERSBURG, Md. and VIENNA, Austria, Nov. 12, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today that its group company and wholly owned subsidiary Ares Genetics GmbH ...
A rapid molecular testing quality initiative to reduce targeted treatment delays in hospitalized patients with new advanced non-small cell lung cancer (aNSCLC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results